𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients

✍ Scribed by Teerha Piratvisuth, Patrick Marcellin, Matei Popescu…

Book ID
120902049
Publisher
Springer-Verlag
Year
2011
Tongue
English
Weight
399 KB
Volume
7
Category
Article
ISSN
1936-0533

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prediction of sustained response to pegi
Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen–positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline
✍ Milan J. Sonneveld; Vincent Rijckborst; Charles A. B. Boucher; Bettina E. Hansen 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 231 KB 👁 1 views

Serum hepatitis B surface antigen (HBsAg) levels may reflect the immunomodulatory efficacy of pegylated interferon (PEG-IFN). We investigated within a large randomized trial whether quantitative HBsAg levels predict response to PEG-IFN in patients with hepatitis B e antigen (HBeAg)-positive chronic

Hepatitis B e antigen as a predictor for
Hepatitis B e antigen as a predictor for hepatitis B e antigen–positive chronic hepatitis B patients with peginterferon alfa-2a therapy
✍ En-Qiang Chen; Hong Tang 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 42 KB 👁 2 views

PROVE1 trial, 1 in which in the group with an identical treatment schedule, the percentage of patients obtaining SVR with respect to RVR was 75% only. In other words, RVR seems easier to obtain with telaprevir, but less frequently predicts a favorable treatment outcome. A possible explanation might

Hepatitis B virus surface antigen levels
Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B
✍ Maurizia Rossana Brunetto; Francesco Moriconi; Ferruccio Bonino; George K. K. La 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 748 KB

Bristol-Myers Squibb, Gilead, and Novartis. He is also in the speakers' bureau of Schering-Plough. Dr. Lau is on the speakers' bureau of and received grants from Roche and Novartis. Dr. Piratvisuth advises and is on the speakers' bureau of Roche. He advises Novartis and Schering-Plough and is on th